Stefan Leucht1, Myrto Samara2, Stephan Heres2, Maxine X Patel3, Toshi Furukawa4, Andrea Cipriani5, John Geddes5, John M Davis6. 1. Department of Psychiatry and Psychotherapy, Technische Universität München Klinikum rechts der Isar, Ismaningerstr. 22, 81675 Munich, Germany; Institute of Psychiatry, Psychology and Neuroscience, King's College London, Department of Psychosis Studies, London, UK; Stefan.Leucht@lrz.tum.de. 2. Department of Psychiatry and Psychotherapy, Technische Universität München Klinikum rechts der Isar, Ismaningerstr. 22, 81675 Munich, Germany; 3. Institute of Psychiatry, Psychology and Neuroscience, King's College London, Department of Psychosis Studies, London, UK; 4. Departments of Health Promotion and Human Behavior and of Clinical Epidemiology, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan; 5. Department of Psychiatry, University of Oxford, Oxford, UK; 6. Psychiatric Institute, University of Illinois at Chicago, Chicago, IL.
Abstract
BACKGROUND: The concept of dose equivalence is important for many purposes. The classical approach published by Davis in 1974 subsequently dominated textbooks for several decades. It was based on the assumption that the mean doses found in flexible-dose trials reflect the average optimum dose which can be used for the calculation of dose equivalence. We are the first to apply the method to second-generation antipsychotics. METHODS: We searched for randomized, double-blind, flexible-dose trials in acutely ill patients with schizophrenia that examined 13 oral second-generation antipsychotics, haloperidol, and chlorpromazine (last search June 2014). We calculated the mean doses of each drug weighted by sample size and divided them by the weighted mean olanzapine dose to obtain olanzapine equivalents. RESULTS: We included 75 studies with 16 555 participants. The doses equivalent to 1 mg/d olanzapine were: amisulpride 38.3 mg/d, aripiprazole 1.4 mg/d, asenapine 0.9 mg/d, chlorpromazine 38.9 mg/d, clozapine 30.6 mg/d, haloperidol 0.7 mg/d, quetiapine 32.3mg/d, risperidone 0.4 mg/d, sertindole 1.1 mg/d, ziprasidone 7.9 mg/d, zotepine 13.2 mg/d. For iloperidone, lurasidone, and paliperidone no data were available. CONCLUSIONS: The classical mean dose method is not reliant on the limited availability of fixed-dose data at the lower end of the effective dose range, which is the major limitation of "minimum effective dose methods" and "dose-response curve methods." In contrast, the mean doses found by the current approach may have in part depended on the dose ranges chosen for the original trials. Ultimate conclusions on dose equivalence of antipsychotics will need to be based on a review of various methods.
BACKGROUND: The concept of dose equivalence is important for many purposes. The classical approach published by Davis in 1974 subsequently dominated textbooks for several decades. It was based on the assumption that the mean doses found in flexible-dose trials reflect the average optimum dose which can be used for the calculation of dose equivalence. We are the first to apply the method to second-generation antipsychotics. METHODS: We searched for randomized, double-blind, flexible-dose trials in acutely ill patients with schizophrenia that examined 13 oral second-generation antipsychotics, haloperidol, and chlorpromazine (last search June 2014). We calculated the mean doses of each drug weighted by sample size and divided them by the weighted mean olanzapine dose to obtain olanzapine equivalents. RESULTS: We included 75 studies with 16 555 participants. The doses equivalent to 1 mg/d olanzapine were: amisulpride 38.3 mg/d, aripiprazole 1.4 mg/d, asenapine 0.9 mg/d, chlorpromazine 38.9 mg/d, clozapine 30.6 mg/d, haloperidol 0.7 mg/d, quetiapine 32.3mg/d, risperidone 0.4 mg/d, sertindole 1.1 mg/d, ziprasidone 7.9 mg/d, zotepine 13.2 mg/d. For iloperidone, lurasidone, and paliperidone no data were available. CONCLUSIONS: The classical mean dose method is not reliant on the limited availability of fixed-dose data at the lower end of the effective dose range, which is the major limitation of "minimum effective dose methods" and "dose-response curve methods." In contrast, the mean doses found by the current approach may have in part depended on the dose ranges chosen for the original trials. Ultimate conclusions on dose equivalence of antipsychotics will need to be based on a review of various methods.
Authors: Anthony F Lehman; Jeffrey A Lieberman; Lisa B Dixon; Thomas H McGlashan; Alexander L Miller; Diana O Perkins; Julie Kreyenbuhl Journal: Am J Psychiatry Date: 2004-02 Impact factor: 18.112
Authors: Stephan Heres; John Davis; Katja Maino; Elisabeth Jetzinger; Werner Kissling; Stefan Leucht Journal: Am J Psychiatry Date: 2006-02 Impact factor: 18.112
Authors: Lisa Hartling; Ahmed M Abou-Setta; Serdar Dursun; Shima S Mousavi; Dion Pasichnyk; Amanda S Newton Journal: Ann Intern Med Date: 2012-10-02 Impact factor: 25.391
Authors: Jian-Ping Zhang; Juan A Gallego; Delbert G Robinson; Anil K Malhotra; John M Kane; Christoph U Correll Journal: Int J Neuropsychopharmacol Date: 2012-12-03 Impact factor: 5.176
Authors: Robert C Wolf; Mahmoud Rashidi; Stefan Fritze; Katharina M Kubera; Georg Northoff; Fabio Sambataro; Vince D Calhoun; Lena S Geiger; Heike Tost; Dusan Hirjak Journal: Schizophr Bull Date: 2020-07-08 Impact factor: 9.306
Authors: Dusan Hirjak; Mahmoud Rashidi; Katharina M Kubera; Georg Northoff; Stefan Fritze; Mike M Schmitgen; Fabio Sambataro; Vince D Calhoun; Robert C Wolf Journal: Schizophr Bull Date: 2020-01-04 Impact factor: 9.306
Authors: Walter Dunn; Yuri Rassovsky; Jonathan Wynn; Allan D Wu; Marco Iacoboni; Gerhard Hellemann; Michael F Green Journal: J Neural Transm (Vienna) Date: 2017-07-07 Impact factor: 3.575
Authors: Jakob Wasserthal; Klaus H Maier-Hein; Peter F Neher; Georg Northoff; Katharina M Kubera; Stefan Fritze; Anais Harneit; Lena S Geiger; Heike Tost; Robert C Wolf; Dusan Hirjak Journal: Neuropsychopharmacology Date: 2020-05-05 Impact factor: 7.853
Authors: Juan Antonio García-Carmona; Jorge Simal-Aguado; María Pilar Campos-Navarro; Francisco Valdivia-Muñoz; Alejandro Galindo-Tovar Journal: Clin Drug Investig Date: 2020-05 Impact factor: 2.859
Authors: Jennifer A Watt; Tara Gomes; Susan E Bronskill; Anjie Huang; Peter C Austin; Joanne M Ho; Sharon E Straus Journal: CMAJ Date: 2018-11-26 Impact factor: 8.262
Authors: Zainab Al-Dhaher; Sandeep Kapoor; Ema Saito; Scott Krakower; Lisa David; Theodore Ake; John M Kane; Christoph U Correll; Maren Carbon Journal: J Child Adolesc Psychopharmacol Date: 2016-04-19 Impact factor: 2.576